sellWeak10b5-1 plan
Carl Dambkowski sold $455k of APGE
Chief Medical Officer at Apogee Therapeutics, Inc.. 10,090 shares at an average of $45.09, traded Jul 2, 2025, filed Jul 3, 2025.
Warning score
0Value
$455k
10,090 shares
Holdings after
238,998
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +17Trade size$455k at market
- 0Share of holdings soldSold 4.1% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-25-065888, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 2, 2025 | MOption exercise Common Stock10b5-1 | +7,365 | $22.86 | $168k | 249,088 | Jul 3, 2025 |
| Jul 2, 2025 | SOpen-market sale Common Stock10b5-1 | -6,409 | $44.77 | $287k | 242,679 | Jul 3, 2025 |
| Jul 2, 2025 | SOpen-market sale Common Stock10b5-1 | -2,935 | $45.49 | $134k | 239,744 | Jul 3, 2025 |
| Jul 2, 2025 | SOpen-market sale Common Stock10b5-1 | -746 | $46.26 | $35k | 238,998 | Jul 3, 2025 |
| Jul 2, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,365 | $0.00 | $0 | 164,010 | Jul 3, 2025 |
Related signals
Other insiders at Apogee Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $120k 1,500 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.5M 20,000 shares | -2% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $3.0M 40,000 shares | -3% | |
| 27Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $113k 1,500 shares | -1% | |
| 32Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $818k 10,900 shares | -4% | |
| 27Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $105k 1,500 shares | -1% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $130k 2,000 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.3M 20,000 shares | -2% | |
| 24Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $60k 1,000 shares | -0% | |
| 14Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $594k 10,785 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.